The property developer has backed Chinese Academy of Medical Sciences spinout Juventas to help advance its clinical-stage oncology cell therapy candidates.

Juventas, a China-based immunotherapy developer based on research at Chinese Academy of Medical Sciences, raised $65m in funding on Wednesday. The company did not identify investors, however, DealStreetAsia reported it was led by private equity fund CMG-SDIC Capital and backed by commercial property developer Parkland Group. The round also included Kaixin Biotechnology – possibly part…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.